RxDoctor Payments Data

Mark Ryan, MD

Internal Medicine · Pensacola, FLNPI 1659513919

Payments from drug & device makers

$8,065in general payments, 2019–2025

Across 487 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$982
  • AbbVie$633
  • Amgen$597
  • AstraZeneca$414
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,026100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,065 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$835,069
Medicare patients
747
Services billed
31,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide269$322,468
EliquisApixaban114$124,176
OzempicSemaglutide94$107,574
JardianceEmpagliflozin50$54,659
RybelsusSemaglutide26$51,046
Synjardy XrEmpagliflozin/Metformin Hcl31$40,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$37,411
LinzessLinaclotide32$35,046
XifaxanRifaximin11$33,683
Soliqua 100-33Insulin Glargine/Lixisenatide22$33,638
MyrbetriqMirabegron43$33,262
ShingrixVaricella-Zoster Ge/As01b/Pf115$25,519
Repatha SureclickEvolocumab14$19,725
TrulicityDulaglutide22$19,527
Janumet XrSitagliptin Phos/Metformin Hcl19$14,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$982$341,994291 claims
Novo NordiskOzempic, Rybelsus$1,469$158,619120 claims
PfizerEliquis, Premarin$1,088$132,326130 claims
Boehringer IngelheimJardiance, Synjardy Xr$137$94,73081 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Breo Ellipta$326$83,259202 claims
AbbVieLinzess, Synthroid$633$41,157132 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$122$33,68311 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$54$33,63822 claims
Astellas Pharma US IncMyrbetriq$62$33,26243 claims
MerckJanumet Xr$16$14,08319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →